Abstract:Chronic liver diseases are common worldwide, especially in developing countries. The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/(COVID-19) leads to the infection of many patients with underlying chronic liver diseases. As a relatively new disease, management of COVID-19, in the context of chronic liver disease, is mainly based on the experience of the treating physician and the available data. In this review, we summarize the available evidence about the management of liver disease patients, in the context of COVID-19 infection, which can increase the severity of viral hepatitis B. Also, its clearance in HBV patients is delayed. A sixfold increased severity of COVID-19 was reported in obese patients with metabolic associated fatty liver disease (MAFDL). In patients with autoimmune liver disease (AILD), it is not recommended to change their immunosuppressive therapy (as long as they are not infected with COVID-19), in order to avoid a flare of liver disease. However, immunosuppressant drugs should be modified, in the case of infection with COVID-19. To date, no data suggest an increased risk or severity in metabolic liver diseases, such as hemochromatosis, Wilson's disease, or alpha-1 antitrypsin deficiency. Patients with liver cirrhosis should be carefully managed with minimum exposure to healthcare facilities. Basic investigations for follow-up can be scheduled at wider intervals; if patients need admission, this should be in COVID-19-clean areas. Patients with hepatocellular carcinomas may have a poor prognosis according to preliminary reports from China. The course of COVID-19 in liver transplant recipients on immunosuppression seems to have a benign course, based on few reports in children and adults. The hepatotoxicity of COVID-19 drugs ranges from mild liver enzyme elevation to a flare of underlying liver diseases. Therefore, the decision should be customized. Telemedicine can minimize the exposure of healthcare workers and patients to infection with COVID-19 and decrease the consumption of personal protective equipment.

Recent challenges facing patients with preexisting chronic liver disease in the era of the COVID-19 pandemic

Management of liver disease patients in different clinical situations during COVID-19 pandemic

Liver injury in severe COVID-19 infection: current insights and challenges

COVID-19 in Individuals with Chronic Liver Diseases

Recent advances in COVID-19-induced liver injury: causes, diagnosis, and management

Management of COVID-19 patients with chronic liver diseases and liver transplants

Effect of COVID-19 on patients with compensated chronic liver diseases

Impact of chronic liver disease on outcomes of hospitalized patients with COVID‐19: A multicentre United States experience

Pathogenetic Mechanisms of Liver-Associated Injuries, Management, and Current Challenges in COVID-19 Patients

Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper

COVID-19 and the liver: What do we know so far?

The Interplay of Chronic Hepatitis C and COVID-19: Implications for Prognosis and Treatment

COVID-19-related liver injury: Mechanisms, diagnosis, management; its impact on pre-existing conditions, cancer and liver transplant: A comprehensive review

Point-of-Care Echocardiography and Hemodynamic Monitoring in Cirrhosis and Acute-on-Chronic Liver Failure in the COVID-19 Era

Abnormal liver function on admission predicts severe outcomes in COVID-19 patients: a multicenter study (Preprint)

COVID-19 is Associated with a High Prevalence of Liver Damage: a Systematic Review and Meta-Analysis

Epidemiological and Clinical Characteristics of 70 Cases of Coronavirus Disease and Concomitant Hepatitis B Virus Infection: A Multicentre Descriptive Study

Liver Diseases in COVID-19: Etiology, Treatment and Prognosis

COVID-19 and Fatty Liver Disorders

Current epidemiology of chronic liver disease

The impact of COVID-19 on the clinical course and outcome of patients with cirrhosis: An observational study